Edition:
United States

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

6.90USD
2:39pm EST
Change (% chg)

$-0.06 (-0.86%)
Prev Close
$6.96
Open
$6.90
Day's High
$6.95
Day's Low
$6.76
Volume
8,134
Avg. Vol
49,412
52-wk High
$8.37
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Thursday, 21 Dec 2017 04:30pm EST 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 03:00am EST 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 06:21am EST 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Wednesday, 1 Nov 2017 04:30pm EDT 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

JDRF, VTV Therapeutics collaborate on Phase 2 study of novel treatment for type 1 diabetes
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - VTV Therapeutics Inc :JDRF and VTV Therapeutics announce collaboration on Phase 2 study of novel treatment for Type 1 diabetes.VTV Therapeutics Inc - JDRF has committed $3 million to study, and VTV will contribute an equal amount.VTV Therapeutics - study is designed to evaluate whether TTP399 is well tolerated when administered as an add-on to insulin therapy for people with T1D.  Full Article

vTv Therapeutics Q2 loss per share $0.41
Wednesday, 2 Aug 2017 04:30pm EDT 

Aug 2 (Reuters) - vTv Therapeutics Inc :vTv Therapeutics reports second quarter 2017 financial and operational results.Q2 gaap loss per share $0.41.Q2 earnings per share view $-0.43 -- Thomson Reuters I/B/E/S.vTv Therapeutics Inc - ‍cash and cash equivalents as of june 30, 2017 were $32.5 million compared to $45.2 million as of March 31, 2017​.vTv Therapeutics Inc - ‍expects cash, cash equivalents will be sufficient to fund its operations through to early 2018​.vTv Therapeutics Inc - ‍expected to report top-line results from part A and B of steadfast study in early 2018 and late 2018, respectively​.  Full Article

VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon
Thursday, 1 Jun 2017 07:00am EDT 

June 1 (Reuters) - Vtv Therapeutics Inc :VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease.VTV Therapeutics completes enrollment of part B of pivotal phase III steadfast trial evaluating Azeliragon for the treatment of patients with mild alzheimer’s disease.VTV Therapeutics - ‍phase 2B results of 5mg per day of azeliragon over period of 18 months showed statistically significant benefit in mild-to-moderate alzheimer's patients​.  Full Article

VTV Therapeutics on March 24, 2017 borrowed $7.5 mln representing second tranche under venture loan, security agreement dated Oct 28 2016
Monday, 27 Mar 2017 04:52pm EDT 

VTV Therapeutics Inc : VTV Therapeutics Inc - on march 24, 2017,co borrowed $7.5 million representing second tranche under venture loan, security agreement dated Oct 28, 2016 . VTV Therapeutics - in connection with borrowing, co issued to lenders warrants to purchase 38,006 shares of class a common stock at per share exercise price of $5.92 .VTV Therapeutics Inc says warrants will expire on October 28, 2023.  Full Article

vTv Therapeutics Q4 net loss per share of class A common stock $0.42
Monday, 27 Feb 2017 07:52pm EST 

vTv Therapeutics Inc : vTv Therapeutics reports 2016 fourth quarter and full year financial and operational results and recent highlights . vTv Therapeutics - believes cash and cash equivalents, funds from its credit facility will be sufficient to fund operations through Q1 of 2018 .Qtrly net loss per share of vTv Therapeutics Inc class A common stock $0.42.  Full Article

vTv Therapeutics Q4 net loss per share of class A common stock $0.42
Monday, 27 Feb 2017 06:15pm EST 

vTv Therapeutics Inc : vTv Therapeutics reports 2016 fourth quarter and full year financial and operational results and recent highlights . vTv Therapeutics - believes cash and cash equivalents, funds from its credit facility will be sufficient to fund operations through Q1 of 2018 .Qtrly net loss per share of vTv Therapeutics Inc class A common stock $0.42.  Full Article

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM